Future Developments in the Treatment of AL Amyloidosis
The treatment of AL amyloidosis has evolved, and outcomes have improved, but primarily for patients with low or intermediate-risk disease. Recent advances have been limited to improvements in anti-clonal therapies, which, alone, cannot change the poor prognosis of patients with high-risk disease. Th...
| Main Authors: | , , , |
|---|---|
| Formato: | Artigo |
| Idioma: | English |
| Publicado em: |
MDPI AG
2022-02-01
|
| Colecção: | Hemato |
| Assuntos: | |
| Acesso em linha: | https://www.mdpi.com/2673-6357/3/1/12 |